Alliance Pharma plc (AIM: APH)

Market Cap	227.04M
Revenue (ttm)	180.68M
Net Income (ttm)	-33.14M
Shares Out	540.57M
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	9.57
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,754,763
Open	42.00
Previous Close	42.00
Day's Range	41.45 - 42.75
52-Week Range	24.55 - 50.40
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 20, 2024

About Alliance Pharma

Alliance Pharma plc acquires, markets, and distributes consumer healthcare products and prescription medicines in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. It provides its products under the Aloclair, Anbesol, Asthon & Parsons, Forceval, Hydromol, Kelo-Cote, MacuShield, Vamousse, Nizoral, and Amberen brand names. The company was incorporated in 1996 and is headquartered in Chippenham, the United Kingdom.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1996
• Employees: 292
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: APH

Financial Performance

In 2023, Alliance Pharma's revenue was 180.68 million, an increase of 7.92% compared to the previous year's 167.42 million. Losses were -33.14 million, 56.2% more than in 2022.